Telomir Pharmaceuticals (TELO) & Its Competitors Financial Contrast

Telomir Pharmaceuticals (NASDAQ:TELO) is one of 1,072 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare Telomir Pharmaceuticals to related companies based on the strength of its risk, earnings, institutional ownership, dividends, valuation, analyst recommendations and profitability.

Risk & Volatility

Telomir Pharmaceuticals has a beta of 0.01, meaning that its share price is 99% less volatile than the S&P 500. Comparatively, Telomir Pharmaceuticals’ peers have a beta of 3.84, meaning that their average share price is 284% more volatile than the S&P 500.

Profitability

This table compares Telomir Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-1,170.58%	-832.67%
Telomir Pharmaceuticals Competitors	-3,399.87%	-235.11%	-32.77%

Insider & Institutional Ownership

44.0% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 13.7% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Telomir Pharmaceuticals and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	0	0	1	1	3.50
Telomir Pharmaceuticals Competitors	8443	22305	50503	1353	2.54

Telomir Pharmaceuticals currently has a consensus target price of $15.00, suggesting a potential upside of 466.04%. As a group, “Pharmaceutical preparations” companies have a potential upside of 256.11%. Given Telomir Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts clearly believe Telomir Pharmaceuticals is more favorable than its peers.

Valuation & Earnings

This table compares Telomir Pharmaceuticals and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	-$16.53 million	-4.57
Telomir Pharmaceuticals Competitors	$9.89 billion	$136.37 million	-5.58

Telomir Pharmaceuticals’ peers have higher revenue and earnings than Telomir Pharmaceuticals. Telomir Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

Telomir Pharmaceuticals peers beat Telomir Pharmaceuticals on 8 of the 13 factors compared.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.